GlassScriptPhysician profile
Javier R Canon
NPI 1518938497
$1,851.64
in general payments reported to CMS, 2019-2025
22 companies · $92.00 in 2025
The $92.00 reported for 2025 was less than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
See the full distribution for Pain Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $635 · 2021: $151 · 2022: $193 · 2023: $227 · 2024: $354 · 2025: $92.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $395.09 | 2020 | |
| Abbott Laboratories | $335.71 | 2019-2024 | Proclaim |
| Boston Scientific Corporation | $148.36 | 2021 | |
| Nevro Corp. | $145.16 | 2019-2020 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $95.44 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.86 | 2022-2023 | |
| Biotissue Holdings INC. | $69.59 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $65.43 | 2022-2023 | Seglentis |
| Horizon Therapeutics Plc | $57.95 | 2020-2022 | |
| Novo Nordisk INC | $56.53 | 2023-2024 | Ozempic, Rybelsus |
| Bioventus LLC | $45.23 | 2020 | |
| Madrigal Pharmaceuticals | $38.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $38.56 | 2023 | Mounjaro, Jardiance |
| Depuy Synthes Sales INC. | $35.54 | 2022-2023 | Monovisc, Orthovisc |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $31.09 | 2020 | |
| Phathom Pharmaceuticals, INC. | $28.94 | 2024 | Voquezna |
| Stryker Corporation | $28.75 | 2023 | Flexible Guide Pin (Stryker Acl Versitomic) |
| Fidia Pharma USA INC. | $22.38 | 2020 | |
| Next Science LLC | $18.30 | 2023 | Blastx, Surgx, Xperience |
| Novartis Pharmaceuticals Corporation | $12.30 | 2022 | |
| Ermi LLC | $2.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Canon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.